Precision oncology begins with access - to the right data, at the right time, and in the right context. At Genomenon, we recognize the critical role that high-quality genomic insights play in identifying disease drivers and guiding treatment decisions. That’s why CKB CORE offers free, ongoing access to expertly curated variant data for 50 cancer-relevant genes.
CKB CORE is designed for both stability and adaptability: 36 Core Oncology Genes are available year-round, and a 14-gene thematic set is refreshed each quarter to align with emerging science and clinical momentum.
Anchored in Evidence, Aligned with Progress: What Our Genes Cover
- 36 Core Oncology Genes (year-round) form the molecular backbone of cancer interpretation - high-frequency, high-impact genes tied to onset, progression, sensitivity, resistance, and prognosis.
- 14 Thematic Genes (updated quarterly) spotlight areas of active interest - new targets, approvals, and evolving regulatory focus.
Together, these 50 curated genes provide a strong foundation for diagnostics, interpretation, and therapeutic relevance.
This Quarter’s Theme: Tumor Suppressor Genes
Tumor suppressor genes act as the cellular brakes - regulating growth, safeguarding genomic integrity, and enforcing checkpoints. When they’re inactivated, the brakes come off.
This quarter in CKB CORE, you’ll find 28 Tumor Suppressor genes spanning key pathways and processes:
- DNA damage sensing & repair (e.g., ATM/ATR axis, HR and MMR components)
- Cell-cycle control & checkpoints (e.g., TP53, RB1, CDKN2A, CHEK1/2)
- Chromatin remodeling (e.g., SWI/SNF complex members such as SMARCA4, SMARCB1, SMARCE1, ARID2, ARID1B, PBRM1)
- Growth/survival signaling (e.g., PTEN, TSC1, TSC2)
- Developmental & WNT/β-catenin regulation (e.g., APC)
Where Insight Meets Action: CKB in the Oncology Workflow
For clinical laboratories
CKB accelerates interpretation with literature-anchored insights on sensitivity, resistance, and clinically observed variants - streamlining workflows, improving report confidence, and supporting evidence-based care.
For researchers
CKB removes manual searching by organizing variants with context - enabling hypothesis generation, target prioritization, and study design grounded in real-world evidence.
For pharma & biotech
CKB supports biomarker discovery, development strategy, and trial design with curated visibility into druggable variants, resistance patterns, and co-occurrence - clarifying opportunities and competitive landscapes.
Go Deeper with CKB BOOST and CKB FLEX
While CORE delivers essential access, some programs demand broader coverage. CKB BOOST unlocks the full depth of our curation engine - 2,200+ expertly curated genes and 49,000+ variants - with literature-backed annotations, therapeutic relevance, and clinical trial connections across tumor types, and biomarkers.
Increased data volume and complexity resulting from NGS testing can lead to missed treatment opportunities for a patient if you don’t have access to a comprehensive dataset that comprises functional variant interpretation and relevant therapeutic options, including clinical trials.
CKB FLEX is downloadable, a professionally curated oncology knowledgebase for scalable, flexible integration into clinical and research workflows.
- Genes: 2,200+
- Variants: 49,000+
- Targeted therapies: 5,600+
- Clinical trials curated: 16,000+
CONCLUSION
Precision oncology isn’t solved by sequencing alone - it’s solved by interpretation. Genomenon helps close that gap with expertly curated variant insights across 50 high-impact cancer genes, giving researchers, clinicians, and developers evidence they can act on. Yet cancer is a moving target - many diseases, many pathways, frequent change - so meaningful progress requires wider coverage.
CKB BOOST delivers that breadth, extending access to 2,200+ curated genes and 49,000+ variants spanning major tumor types, therapeutic areas, and emerging targets. From common biomarkers to rare variants, CKB BOOST provides the fuller picture required for confident, high-impact decisions - because in oncology, the right variant data isn’t a luxury; it’s essential.
Contact us today to learn how you can access the standard in evidence-based care!
